Reports Q3 revenue $1.43B, consensus $1.42B. “Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Resmed’s (RMD) Chairman and CEO, Mick Farrell.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Notable companies reporting after market close
- RMD Earnings this Week: How Will it Perform?
- ResMed price target lowered to $290 from $302 at KeyBanc
- ResMed Steps Up PAP Innovation With New Amalfi vs. CLA11 Sleep Apnea Study
- ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks